Ulcerative colitis in adults: A review

B Gros, GG Kaplan - Jama, 2023 - jamanetwork.com
Importance Ulcerative colitis (UC) is a chronic inflammatory condition of the colon, with a
prevalence exceeding 400 per 100 000 in North America. Individuals with UC have a lower …

The JAK/STAT signaling pathway: from bench to clinic

X Hu, J Li, M Fu, X Zhao, W Wang - Signal transduction and targeted …, 2021 - nature.com
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

ECCO guidelines on therapeutics in ulcerative colitis: medical treatment

T Raine, S Bonovas, J Burisch… - Journal of Crohn's …, 2022 - academic.oup.com
Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterised by colonic
inflammation extending to a variable extent from the rectum. Care of the patient with UC …

Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

JS Lasa, PA Olivera, S Danese… - The Lancet …, 2022 - thelancet.com
Background There is a growing armamentarium for the treatment of moderate-to-severe
ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small …

ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease

T Kucharzik, P Ellul, T Greuter, JF Rahier… - Journal of Crohn's …, 2021 - academic.oup.com
The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

GR Burmester, SB Cohen, KL Winthrop, P Nash… - RMD open, 2023 - rmdopen.bmj.com
Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD) …

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

B Combe, A Kivitz, Y Tanaka… - Annals of the …, 2021 - ard.bmj.com
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …

International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease

PA Olivera, S Zuily, PG Kotze, V Regnault… - Nature Reviews …, 2021 - nature.com
Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events.
Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based …

ECCO guidelines on inflammatory bowel disease and malignancies

H Gordon, L Biancone, G Fiorino… - Journal of Crohn's …, 2023 - academic.oup.com
This guideline is the second European Crohn's and Colitis Organisation [ECCO] evidence-
based consensus on inflammatory bowel disease [IBD] and malignancy, and is an update …

Versatile carbon dots with superoxide dismutase-like nanozyme activity and red fluorescence for inflammatory bowel disease therapeutics

Y Ma, J Zhao, L Cheng, C Li, X Yan, Z Deng, Y Zhang… - Carbon, 2023 - Elsevier
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease
(CD), is a chronic and recurrent disease that seriously affects the life quality of patients …